NAV

αAβ–Gas6

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

αAβ–Gas6 is a chimeric fusion protein being investigated for Alzheimer's disease.

Generic Name
αAβ–Gas6
DrugBank Accession Number
DB17069
Background

αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand for receptor kinases expressed in glial cells.1,2 αAβ–Gas6 is a phagocyte inducer of Aβ,1 which is the main component of the amyloid plaques found in individuals with AD and is considered to contribute to the pathophysiology of AD.3 This experimental drug gained attention because it was associated with fewer inflammatory side effects than the previously-approved Aβ antibody-based immunotherapy, aducanumab.6

Type
Biotech
Groups
Experimental
Biologic Classification
Protein Based Therapies
Fusion proteins
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

TAM (TYRO3, AXL, and MERTK) receptors are receptor tyrosine kinases expressed ubiquitously,4 including microglia and astrocytes of the nervous system.1 They play a critical role in homeostatic processes such as phagocytosis of apoptotic cells and membranous organelles, and regulation of inflammatory responses and inflammation.5,4

αAβ-Gas6 targets TAM receptors by binding to growth arrest-specific 6 (Gas6), a ligand for TAM receptors.2 By activating the TAM receptor signalling pathway, αAβ-Gas6 promotes TAM receptor-dependent phagocytosis to selectively eliminate Aβ plaques without affecting NF-kB-mediated inflammatory responses or reactive gliosis.1

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Jung H, Lee SY, Lim S, Choi HR, Choi Y, Kim M, Kim S, Lee Y, Han KH, Chung WS, Kim CH: Anti-inflammatory clearance of amyloid-beta by a chimeric Gas6 fusion protein. Nat Med. 2022 Sep;28(9):1802-1812. doi: 10.1038/s41591-022-01926-9. Epub 2022 Aug 4. [Article]
  2. Shankar SL, O'Guin K, Cammer M, McMorris FA, Stitt TN, Basch RS, Varnum B, Shafit-Zagardo B: The growth arrest-specific gene product Gas6 promotes the survival of human oligodendrocytes via a phosphatidylinositol 3-kinase-dependent pathway. J Neurosci. 2003 May 15;23(10):4208-18. [Article]
  3. Thal DR, Walter J, Saido TC, Fandrich M: Neuropathology and biochemistry of Abeta and its aggregates in Alzheimer's disease. Acta Neuropathol. 2015 Feb;129(2):167-82. doi: 10.1007/s00401-014-1375-y. Epub 2014 Dec 23. [Article]
  4. Lemke G: Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 2013 Nov 1;5(11):a009076. doi: 10.1101/cshperspect.a009076. [Article]
  5. Lemke G, Rothlin CV: Immunobiology of the TAM receptors. Nat Rev Immunol. 2008 May;8(5):327-36. doi: 10.1038/nri2303. [Article]
  6. SciTechDaily: A New, More Effective Alzheimer’s Drug With No Inflammatory Side Effects [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 13, 2022 14:30 / Updated at December 01, 2022 11:34